Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.